Apexigen, Inc. (APGN)
Apexigen, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Carlos, CA, US. The stock last traded at $0.39, up 8.48% on the session, giving a market capitalisation of $9.6M. On trailing twelve-month figures it carries a trailing P/E of -0.24, a net margin of 0.0%. Its beta of 3.62 implies it has historically moved more than the broad market.
Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.
Apexigen, Inc. is most often compared with the following Healthcare names: